Drug updated on 9/4/2024
Dosage Form | Cream (topical; 10 mg/1 g [1%]) |
Drug Class | Quinolone antimicrobials |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the topical treatment of impetigo due to Staphylococcus aureus Streptococcus pyogenes or in adult and pediatric patients 2 months of age and older.
Latest News
Summary
- Xepi (ozenoxacin) is indicated for the topical treatment of impetigo caused by Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older.
- This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
- Ozenoxacin: In nonendemic settings, ozenoxacin 1% cream demonstrated superior effectiveness in treating impetigo compared to retapamulin and a new minocycline formulation. It was also identified as a costlier but effective alternative to mupirocin and retapamulin.
- Retapamulin: Retapamulin was effective in treating impetigo in nonendemic settings but less so than ozenoxacin. It was effective against lesions colonized by MSSA and Streptococcus pyogenes but not MRSA.
- Oral Co-trimoxazole and Benzathine Benzylpenicillin G: Both treatments were equally effective in treating severe impetigo in endemic settings. Mass drug administration was suggested as a strategy to reduce impetigo prevalence in these settings.
- Adverse events for both ozenoxacin and retapamulin were minimal, with pruritus at the application site being the most commonly reported adverse event.
- All evaluated topical antibiotics demonstrated greater resolution of impetigo with minimal adverse events compared to the vehicle.
- Studies indicate that impetigo primarily affects the pediatric population. Effectiveness of treatments varies by setting, with ozenoxacin and retapamulin being effective in nonendemic settings, while oral co-trimoxazole and benzathine benzylpenicillin G are effective in endemic settings. Mupirocin shows clinical efficacy against MRSA, while retapamulin does not, making bacterial culture necessary to rule out resistance.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Xepi (ozenoxacin) Prescribing Information. | 2017 | Teligent Pharma, Inc., Buena, NJ |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Emerging treatment strategies for impetigo in endemic and nonendemic settings: a systematic review. | 2021 | Clinical Therapeutics |
A comparative review of current topical antibiotics for impetigo. | 2021 | Expert Opinion on Drug Safety |
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Pediatric impetigo: an expert panel opinion about its main controversies. | 2022 | Journal of Chemotherapy |